S
GMAB icon

SignatureFD’s Genmab GMAB Stock Holding History

SignatureFD’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452K Buy
16,442
+662
+4% +$17.6K 0.01% 701
2026
Q1 		$423K Buy
15,780
+711
+5% +$21.3K 0.01% 678
2025
Q4 		$464K Buy
15,069
+720
+5% +$22.4K 0.01% 628
2025
Q3 		$440K Buy
14,349
+5,225
+57% +$127K 0.01% 632
2025
Q2 		$189K Sell
9,124
-1,400
-13% -$28.7K ﹤0.01% 947
2025
Q1 		$206K Sell
10,524
-10,266
-49% -$215K ﹤0.01% 869
2024
Q4 		$434K Buy
20,790
+12,890
+163% +$283K 0.01% 571
2024
Q3 		$193K Buy
7,900
+1,920
+32% +$51.3K ﹤0.01% 886
2024
Q2 		$150K Sell
5,980
-4,109
-41% -$117K ﹤0.01% 960
2024
Q1 		$302K Sell
10,089
-2,448
-20% -$71.9K 0.01% 680
2023
Q4 		$399K Sell
12,537
-4,430
-26% -$139K 0.01% 541
2023
Q3 		$598K Buy
16,967
+1,800
+12% +$68.6K 0.02% 382
2023
Q2 		$576K Buy
15,167
+1,380
+10% +$55K 0.01% 392
2023
Q1 		$521K Sell
13,787
-1,040
-7% -$40K 0.01% 419
2022
Q4 		$628K Buy
14,827
+1,650
+13% +$68K 0.02% 340
2022
Q3 		$423K Buy
13,177
+4,007
+44% +$141K 0.01% 434
2022
Q2 		$298K Sell
9,170
-354
-4% -$11.5K 0.01% 548
2022
Q1 		$345K Sell
9,524
-171
-2% -$5.87K 0.01% 529
2021
Q4 		$384K Buy
9,695
+731
+8% +$30.5K 0.01% 480
2021
Q3 		$392K Buy
8,964
+907
+11% +$40.7K 0.01% 453
2021
Q2 		$329K Sell
8,057
-225
-3% -$8.68K 0.01% 487
2021
Q1 		$272K Buy
8,282
+1,029
+14% +$38.7K 0.01% 479
2020
Q4 		$295K Sell
7,253
-17
-0.2% -$635 0.01% 411
2020
Q3 		$266K Buy
7,270
+3,636
+100% +$131K 0.01% 383
2020
Q2 		$123K Buy
3,634
+483
+15% +$13.2K 0.01% 616
2020
Q1 		$67K Sell
3,151
-1,339
-30% -$29.8K 0.01% 788
2019
Q4 		$100K Buy
4,490
+2,110
+89% +$46K 0.01% 706
2019
Q3 		$48K Buy
+2,380
New +$46.9K ﹤0.01% 939

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SignatureFD's GMAB Position: Q2 2026 in Review

SignatureFD increased its Genmab (GMAB) stake by 4.2% in Q2 2026, buying an estimated $17.6K and bringing the position to 16,442 shares worth $452K. The position accounts for 0.01% of the portfolio, ranked #701.

SignatureFD first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $628K in Q4 2022. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • SignatureFD held 16,442 shares of Genmab worth $452K as of Q2 2026.
  • SignatureFD bought 662 Genmab shares in Q2 2026, an estimated $17.6K.
  • Genmab made up 0.01% of SignatureFD's portfolio in Q2 2026, its #701 holding.
  • SignatureFD first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • SignatureFD's Genmab position peaked at $628K in Q4 2022.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.